Recent genome-wide association studies linked childhood asthma with single-nucleotide polymorphisms (SNPs) in ORM1-like protein 3 (ORMDL3) gene region on chromosome 17q21. We analyzed the effect of functional SNP rs2872507 in ORMDL3 gene region on the response to antiasthmatic treatment with inhaled corticosteroids (ICSs) and ORMDL3 gene expression. Forced expiratory volume in 1 s increased significantly by 13.3% of predicted value after therapy in atopic asthmatics with AA genotype, compared with 7.0% in heterozygotes and 4.9% increase in GG homozygotes (P ¼ 0.0176). Median relative expression of ORMDL3 gene in asthmatics with AA, AG and GG genotypes was 0.75, 1.05 and 1.21, respectively (Po0.0001). Treatment with ICSs was significantly associated with the increase of median relative expression of ORMDL3 gene, from 0.88 to 1.21 (P ¼ 0.0032) in atopic asthmatics. Our results suggest that rs2872507 is associated with ORMDL3 gene expression and with ICS treatment response in children with atopic asthma.
INTRODUCTION
Asthma is a complex polygenic disease with several phenotypes. Inhaled corticosteroids (ICSs) are still the mainstay of the antiasthmatic therapy. ICSs are ineffective in almost a quarter of properly treated asthmatics and the differences in antiasthmatic effect between individuals are mostly genotype dependent. 1 However, until now, only a few genes have been associated with the effect of ICSs in asthma. 2, 3 More asthma pharmacogenomics studies are needed 4, 5 as the exact mechanism of the antiasthmatic effect of ICSs is still unknown; particularly, it is not clear if their anti-inflammatory effect is crucial for successful asthma treatment. 6 More than 100 genes have been linked with asthma in numerous association studies, but these are usually not confirmed in different populations or age groups. 7 The first genome-wide association study in asthma, performed by Moffatt et al., 8 identified single-nucleotide polymorphisms (SNPs) in the noncoding part or near the ORM1-like protein 3 (ORMDL3) gene at locus 17q21 that confer an increased risk of childhood asthma and influence ORMDL3 and adjacent gasdermin B (GSDMB) gene expression. The association of 17q21 variants with childhood asthma has been subsequently confirmed in ethnically diverse populations. 9 SNP rs2872507, which influences ORMDL3 gene expression, has been significantly associated with asthma 10, 11 and with other inflammatory or autoimmune diseases like Crohn's disease, ankylosing spondylitis or type I diabetes. [12] [13] [14] Furthermore, SNPs rs2872507 and rs2305480, originally reported as the most significant asthma-associated SNPs from 17q21 region, are in strong linkage disequilibrium (r 2 ¼ 0.99).
ORMDL3 gene is ubiquitously expressed and encodes a protein integrated in the endoplasmic reticulum membrane. 15 ORM proteins have been recently identified as important downregulators of sphingolipid synthesis in the endoplasmic reticulum. 16 Sphingolipids are plasma membrane lipids that can be rapidly metabolized to ceramide or further to sphingosine and its more active metabolite sphingosine-1-phosphate (S1P).
17 S1P receptor (S1PR) activation is crucial for initiation of lung immune responses by mature antigen-presenting cells. 18 In addition to their direct effect on the immune system, sphingolipids and their products also exert influence on the fundamental cell signaling systems transducing nonspecific stimuli of inflammation. Sphingolipids stimulate mitogen-activated protein kinase and pro-inflammatory transcription factor nuclear factor-kB, which is ubiquitously expressed and induces over 150 genes, many of them encoding pro-inflammatory cytokines and chemokines. 19, 20 Although polymorphisms in the ORMDL3 gene region were investigated as risk factors for asthma, no studies exist to test ORMDL3 polymorphisms as pharmacogenomics markers in ICS treatment response in childhood asthma. Because corticosteroids are also known to play a role in a wide range of anti-inflammatory effects and are the mainstay of therapy for patients with asthma, 21 we performed a pharmacogenetic study to test the hypothesis that SNP rs2872507 in ORMDL3 gene region influences the antiasthmatic effect of ICSs. To further elucidate the underlying mechanism of genetic association, we extended the association study with the expression analysis where we tested the hypothesis that SNP rs2872507 and antiasthmatic treatment both influence ORMDL3 gene expression. Our study is the first report of genetic association of a 17q21 variant with the antiasthmatic effect of ICSs.
MATERIALS AND METHODS

Participants and study design
We analyzed a case-control cohort composed of 311 children with mild or moderate persistent asthma, aged 5-18 years, and 276 healthy unrelated but age-and sex-matched controls. Patients and controls with DNA samples not passing high-quality control standards were excluded from genotyping and the remaining 300 asthmatics and 251 controls were successfully genotyped (Table 1) . Asthma was diagnosed according to American Thoracic Society (ATS) criteria. 22, 23 Patients were stratified into asthma phenotypes based on the allergy testing. Asthmatics were treated in the Pulmonary and Allergic Outpatient consultation, Department of Pediatric Medicine, General Hospital Murska Sobota (Murska Sobota, Slovenia) and in the Pediatric Pulmonary Outpatients, University Medical Centre Maribor (Maribor, Slovenia) from 1 January 2008 to 31 May 2012. We included all children with mild or moderate persistent asthma newly detected in this period. All patients and controls were Caucasians of Slovenian origin. Patients with other chronic inflammatory diseases except asthma and atopic diseases were excluded from the study. All measurements, blood withdrawal and laboratory tests were done before the initiation of therapy. Assessment of the influence of SNP rs2872507 on the effect of antiasthmatic therapy was performed in 213 asthmatics who were regularly treated with ICSs-200 mg of fluticasone dry powder (Flixotide diskus, GSK Pharmaceuticals SA, Poznań , Poland) per day was prescribed for children o12 years of age and 400 mg daily for older children. Other asthmatics who were treated with other therapies than ICSs (for example, antileukotriens) were not included in the pharmacogenetic part of the study. For gene expression analysis, blood samples were collected from 278 asthmatics before treatment, and 69 matching samples were obtained 4-6 weeks after treatment with ICSs in those patients who agreed with a second blood withdrawal (Table 1) .
Parents signed informed consent for children o15 years, whereas older children gave informed consent by themselves. The study was carried out in accordance with the Helsinki declaration of the World Medical Association (1975) and approved by the Slovenian National Medical Ethics Committee (KME 31/12/06). 24 In asthmatics who were regularly treated with ICSs, spirometry was repeated after 4-6 weeks of treatment. Bronchial hyperreactivity was assessed with a methacholine bronchoprovocation challenge test with dosimeter Provojet (Ganshorn Medizin Electronic, Niederlauer, Germany) and according to ATS guidelines. 25 For online measurement of the FENO, we used a Niox analyzer (Aerocrine, Inc., New Providence, NJ, USA) using the chemiluminescence method for gas analysis. The measurement was done according to ATS/ERS guidelines. 26 From each patient, 12 ml of venous blood was drawn into tubes with EDTA for genetic analysis, an eosinophil count, total IgE and specific IgE analysis.
Measurements and laboratory tests
DNA and RNA extraction
Total blood leukocytes were isolated using Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) gradient centrifugation, according to the manufacturer's instructions. Total RNA and genomic DNA were isolated using QIAzol Lysis Reagent (QIAgen, Valenica, CA, USA). DNA was dissolved in water at a final concentration of 50 ng ml À 1 . RNA concentrations ranged from B0.1 to 1.17 mg ml À 1 as determined by an ND1000 spectrophotometer and NanoDrop 3.0.1 software (NanoDrop Technologies, Wilmington, DE, USA); 260/280 ratios ranged from 1.7 to 2.0. The integrity of RNA samples was analyzed by electrophoresis on a 2% agarose gel. All samples were immediately frozen and stored at À 80 1C.
Genotyping of DNA polymorphism rs2872507
Genotyping was performed by PCR followed by restriction fragment length polymorphism. Primers used for PCR amplification were: forward 5 0 -GG GATACTCAAACTGTATCTTTCC-3 
Gene expression of ORMDL3
First-strand complementary DNA (cDNA) was generated by reverse transcription of 1 mg total RNA per sample with random primers and MultiScribe Reverse Transcriptase (50 U per reaction) using High-Capacity cDNA Reverse Transcription kit (Cat. no. 4368813, Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 20 ml. The first step of reverse transcription reaction was performed at 25 1C for 10 min followed by a 2-h incubation period at 37 1C and finalized with 5 min of incubation at 85 1C, according to the manufacturer's instructions. The cDNA was diluted 1:20 with RNase-free water and stored at À 80 1C.
The intron spanning primers used for ORMDL3, and reference genes ACTB, B2M and GAPDH, amplification were designed using the Universal ProbeLibrary Assay Design Center from Roche Applied Science (https:// www.roche-applied-science.com/sis/rtpcr/upl) and manufactured by Sigma (Munich, Germany). The expression study was performed using a 96-multiwell white plate (Cat. no. 04729692001, Roche Applied Science, Mannheim, Germany) on a Roche LightCycler 480 detection system (Roche Applied Science) with Maxima SYBR Green qPCR Master Mix (Fermentas). Samples were amplified in reactions containing 2 ml of cDNA, 5 ml of 2Â SYBR Green master mix, primers (concentration according to optimized standard curve of each target gene) and RNase-free water in a final reaction volume of 10 ml. The PCR program was initiated at 95 1C for 10 min to activate Taq DNA polymerase, followed by 40 thermal cycles of 15 s at 95 1C, 30 s at 60 1C and 30 s at 72 1C. The specificity analysis of the PCR products (melting curve analysis) was performed after the real-time PCR. The temperature range used for the melting curve generation was from 65 to 95 1C.
Samples were analyzed in duplicate wells and each PCR run included a no-template control using water instead of cDNA. ORDML3 Cq values were normalized using the geometrical mean of reference genes ACTB, B2M and GAPDH Cq values. 27 Relative expression was calculated using the equation 2 
Statistical analysis
Data analysis was carried out using SPSS version 19.0 (SPSS, Chicago, IL, USA). The w 2 test and two-sided Fisher's exact test were used to calculate the significance of differences in allele and genotype frequencies between asthmatics and controls. We calculated odds ratio for asthma with 95% confidence interval. The w 2 test was also used for assessment of Hardy-Weinberg equilibrium. Additive model of genetic association was analyzed with logistic regression adjusting for age and sex. Power of the association study was determined using the tool available at http://pngu.mgh.harvard.edu/Bpurcell/gpc/.
With one-way analysis of variance test followed by Newman-Keuls multiple comparison post hoc test and t-test for two independent samples, we analyzed the influence of genotype on some clinical parameters that are quantitative traits: FENO, logPC 20 
RESULTS
Participants and descriptive data
In the whole group of asthmatics, there were 55.3% (n ¼ 172) males and 44.7% (n ¼ 139) females. The mean age was 11.0±3.2 years, 65.6% of patients (n ¼ 204) were atopic asthmatics, 28.9% (n ¼ 90) had nonatopic asthma and in 5.5% (n ¼ 17) of asthmatics the allergic status remained undetermined.
Genotype and allelic frequencies of SNP rs2872507 Genotype frequencies in the group of asthmatics and in the control group were in Hardy-Weinberg equilibrium (P ¼ 0.913 and P ¼ 0.6583, respectively). According to the dominant model of genetic association, the frequency of GG genotype in asthmatics was 38.0%, which was significantly higher than 29.5% in controls (P ¼ 0.038). We found no differences in the allele frequencies between asthmatics and the control group ( Table 2 ). The power of the association study was calculated to be 0.27 at a 0.05. According to additive model the genotype was not significantly associated with asthma (P ¼ 0.0653). We have also compared genotype and allele frequencies with controls, separately for both asthma phenotypes (atopic and nonatopic), and no significant differences were found between the groups ( Table 2) .
Influence of SNP rs2872507 on the effect of therapy and clinical and laboratory parameters Asthmatics with genotype AA had an 11.1±16.0% mean increase of predicted value of FEV1 after 4-6 weeks of therapy with ICSs, compared with 4.6 ± 9.6% in GG homozygotes (P ¼ 0.0463) (Figure 2 ). The influence of genotype was confirmed with generalized linear model adjusting for age, sex and pretreatment FEV1 as confounders (P ¼ 0.0430). This difference was also significant on the allelic level. Carriers of A allele had a 8.5 ± 13.8% mean increase of predicted value of FEV1 after therapy with ICSs, which was significantly higher than 5.5 ± 10.7% in asthmatics with G allele (P ¼ 0.0150). Change of FEV1 (dFEV1) was not significantly correlated to FEV1 response in the bronchodilating test (Pearson's coefficient 0.085, P ¼ 0.3030). Other clinical and laboratory parameters (FEV1, dFEV1/FVC, total IgE, blood eosinophil, logPC 20 and FENO values) did not significantly differ between genotype groups as shown in Table 3 .
We have also tested the influence of SNP rs2872507 on the effect of therapy separately in atopic and nonatopic asthmatics. In atopic asthmatics with AA genotype, FEV1 increased after the therapy by 13.3±16.3% of predicted value, compared with 7.0 ± 12.1% in AG genotype and 4.9 ± 8.3% in GG genotype group (P ¼ 0.0176; Figure 2 ). The influence of genotype on dFEV1 in atopic asthmatics was confirmed with generalized linear model (P ¼ 0.0102). Allelic analysis showed that in atopic asthmatics with A allele, FEV1 increased by 9.6 ± 14.7% of predicted value after the antiasthmatic therapy, compared with 5.7 ± 9.5% in those with G allele (P ¼ 0.0070). SNP rs2872507 genotype was also associated with higher increase in dFEV1/FVC in atopic asthmatics with AA (Table 3) , whereas other quantitative traits in atopic asthmatics showed no significant association.
In nonatopic asthmatics, no significant influence of genotype on the effect of therapy (dFEV1) or other clinical and laboratory parameters was found with the exception of eosinophil count that was lower in AA genotype according to the recessive model (Table 3) .
ORMDL3 gene expression ORMDL3 median relative expression before therapy in all asthmatics with SNP rs2872507 AA genotype was 0.75 ± 0.47, in those with AG genotype was 1.05±0.61 and in asthmatics with GG genotype was 1.21±0.78 (Figure 3 ). The differences in ORMDL3 gene expression for GG and AG genotype groups compared with AA were statistically highly significant (Po0.0001). Results were confirmed with generalized linear model adjusting for age and gender (Po0.0001). We also analyzed ORMDL3 gene expression according to rs2872507 genotype separately in atopic and nonatopic asthmatics. In atopic asthmatics with AA, AG and GG genotypes, median relative expression was 0.75 ± 0.44, 1.02 ± 0.66 and 1.22 ± 0.63, respectively. Differences were statistically significant for GG and AG genotype groups compared with AA (P ¼ 0.0002). In nonatopic asthmatics with AA, AG and GG genotypes, median relative expression was 0.85±0.52, 1.14±0.54 and 1.17±1.11, respectively. The differences were statistically significant for GG genotype group compared with AA (P ¼ 0.0333). In control group the relative median ORMDL3 gene expression was 0.96±0.78, which was not significantly different from 1.05±0.68 in all asthmatics (P ¼ 0.5437). The ORMDL3 median gene expression in controls with AA (0.82 ± 0.50) and AG (0.92 ± 0.60) genotypes was significantly lower from those with GG (1.35±1.13) genotype (P ¼ 0.0015).
Therapy with ICSs significantly increased ORMDL3 median relative expression from 0.95 ± 0.70 to 1.25 ± 0.90 in asthmatics (P ¼ 0.0143) and from 0.88 ± 0.70 to 1.21 ± 0.82 in atopic asthmatics (P ¼ 0.0032), but not in nonatopic asthmatics (Figure 4) .
When comparing changes in ORMDL3 gene expression levels before and after ICS treatment according to genotype, the median difference in relative expression in asthmatics with AA genotype was 1.26±7.34, with AG was 0.09±1.22 and with GG was 0.12 ± 1.22. However, these differences were not significantly different (P ¼ 0.1872). Results were tested with generalized linear model, adjusting for age, sex and pretreatment gene expression values. With this model we found significant difference in change of ORMDL3 gene expression after treatment according to genotype between AA versus GG (P ¼ 0.0002). Pretreatment levels of gene expression were also found to significantly affect the extent of change of expression after treatment (Po0.0001).
DISCUSSION
In our study we showed that atopic asthmatic children with rs2872507 AA genotype when compared with patients with AG and GG genotypes have better treatment outcome in response to antiasthmatic treatment with ICSs. We also showed that ORMDL3 gene expression is increased after treatment particularly in atopic asthmatics and is associated with rs2872507 genotype in all asthmatics and controls. Our findings may contribute to the understanding of the mechanisms of anti-inflammatory action of corticosteroids and further support the importance of 17q21 chromosome region in asthma.
To the best of our knowledge, there are yet no studies on the influence of 17q21 region on the effect of antiasthmatic treatment with ICSs in children with asthma. ICSs are still the first-line treatment in adults and children with mild and moderate persistent asthma. However, in 425% of asthmatics, they have no significant effect and the response to treatment between individuals is highly variable. 1, 28 Approximately 70% of the variance in ICS response is under the genetic control. 29 Despite these findings, little is known about the pharmacogenetics of corticosteroids in asthma.
Genetic polymorphisms in the CRHR1 gene, which regulates endogenous cortisol synthesis, have been shown to influence the effect of ICSs in childhood asthma. 2 Other studies have focused on ORMDL3 polymorphism and asthma treatment response V Berce et al the pharmacogenetics of the glucocorticoid receptor and the elements of its signal transduction. 30, 31 The only genome-wide association study investigating the genetic background of therapy response to ICSs was performed recently. 32 This study revealed an association between the response to ICSs in asthma with glucocorticoid-induced transcript 1 gene (GLCCI1), which encodes the protein involved in the signal transduction of corticosteroids. 32 In a previous study from our group, the pharmacogenetic effect of the functional SNP CT60 in the gene encoding the cytotoxic T lymphocyte associated antigen 4 (CTLA4), which is one of the key regulators in the process of antigen presentation, was also shown. We have revealed the influence of this polymorphism on the response to treatment with ICSs in children with atopic asthma. 33 However, these studies cannot fully explain the contribution of genetics to the variability of the response to antiasthmatic treatment with ICSs. 34 To the best of our knowledge, our study is the first pharmacogenetic study of ICS treatment response in childhood asthma investigating polymorphisms located near ORMDL3, a gene that encodes a protein involved in sphingolipid metabolism. Our results clearly show ORMDL3 gene expression to be dependent on the functional SNP rs2872507 genotype and association of Table 3 . Influence of rs2872507 genotype on clinical and laboratory parameters in asthmatics ORMDL3 polymorphism and asthma treatment response V Berce et al rs2872507 AA genotype with better response to ICS treatment in atopic asthmatics. The more important role of SNP rs2872507 genotype in atopic asthmatics is not unexpected, as differences in the effects of genotype in atopic and nonatopic asthmatics on asthma and/or asthma traits were observed previously. 35, 36 Typically, glucocorticoids bring about their anti-inflammatory action by binding to the ligand-binding domain of glucocorticoid receptor to promote nuclear translocation. In the nucleus, the DNA-binding domain of glucocorticoid receptor interacts with simple glucocorticoid response elements to transcriptionally activate (transactivate) anti-inflammatory genes. 37 Thus, SNP rs2872507 might influence this route of anti-inflammatory action of glucocorticoids by modifying the transcriptional activation of ORMDL3 in atopic asthmatics. This hypothesis is further supported by our findings that ORMDL3 gene expression was significantly increased after therapy with ICSs in atopic asthmatics. Additionally, we also showed that differences in ORMDL3 gene expression before and after treatment with ICSs have a tendency to be more pronounced in asthmatics with AA rs2872507 genotype rather than with AG or GG genotype. The mechanism by which ORMDL3 gene contributes to asthma pathogenesis has long been unclear. However, it has been recently reported that proteins encoded by highly conserved ORM genes (known as ORMDL in humans) are important negative regulators of sphingolipid metabolism. 16 Sphingolipids are plasma membrane lipids that can be rapidly metabolized to ceramide or further to sphingosine and, the more active metabolite, S1P. Sphingolipids have a profound effect on the lung immune response. 17 They activate pro-inflammatory transcription factors in cell types involved in asthma pathogenesis, such as dendritic cells, lymphocytes T and mastocytes. 17 In asthma model systems, sphingolipids promote airway hyperresponsiveness and proliferation of airway smooth muscle. 38, 39 Sphingolipids were also reported to stimulate mastocyte degranulation and modulate the effect of lipopolysaccharide, which is a key factor in preventing atopy according to the hygiene hypothesis. [40] [41] [42] Therefore, sphingolipids are likely to be involved in atopy and atopic asthma pathogenesis, making ORMDL3 and its related metabolic pathways an important therapeutic target for corticosteroids in atopic asthma phenotype.
The interaction between ORMDL3 and corticosteroids described in our study can also be explained by mechanisms other than airway inflammation. Some investigators recently focused on airway smooth muscle cell abnormalities in asthma and causally linked them to airway hyperreactivity and remodeling. 43 As these abnormalities are sensitive to corticosteroids, 44 and sphingolipids regulate airway smooth muscle function, 45 this is another possible common pathway that links ORMDL3 and corticosteroids.
Some limitations of our study have to be taken into account. Our study relies on a somewhat small sample size, and therefore a replication study to confirm our findings would be helpful. No firm conclusions can be drawn from our study regarding nonatopic asthmatics because of a very limited sample size. After we performed multivariable analysis using generalized linear model test including age and baseline FEV1 as covariates and gender as a factor, we could still confirm the influence of genotype on the effect of treatment with ICSs, although the adjusted P-value approached to the border of marginal significance. Unlike previous association studies, we only found a marginal association of ORMDL3 genotype with childhood asthma, which probably reflects the small power of association part of our study.
In conclusion, we showed that the outcome of treatment with ICSs in atopic asthmatics is influenced by the rs2872507 genotype, and that ORMDL3 gene expression increases after ICS treatment that, in turn, is also associated with rs2872507 genotype. Our study offers new insights into the action of corticosteroids in asthma, suggesting ORMDL3 gene and related metabolic pathways as important targets in the antiasthmatic action of corticosteroids. These findings could lead to a personalized approach to asthma treatment, which should incorporate genotype testing and improve treatment outcome.
